Catalyst Wire Dossier Catalyst Wire Dossier

Trelegy Ellipta (Fluticasone furoate/umeclidinium/vilanterol)

Fluticasone furoate/umeclidinium/vilanterol · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Trelegy Ellipta (Fluticasone furoate/umeclidinium/vilanterol), covering 2026-02-02 to 2026-02-02. Get the full timeline:

Most recent: Clinical Trial Update: Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study [Phase 4]

See pricing